MINNEAPOLIS, MN – Nationally-ranked startup accelerator gener8tor has announced the five companies participating in its gBETA Medtech Spring 2022 cohort. gBETA Medtech’s Spring 2022 cohort kicked off on April 20th and the program will culminate on June 21st, 2022 at “Showcase Day,” which will highlight each
of the five companies. 
Out of the 140+ companies that applied to the program, the gBETA Medtech Spring 2022 cohort selected five companies: Mother of Fact, OmnVis, Q-rounds, SingleTimeMicroneedles and Tiumed. (See company details below.)
This cohort features founders from across the country with expertise in medical devices, diagnostics, testing, and digital health solutions.
gBETA Medtech is a free, seven-week accelerator that works with medical devices, healthcare-related software, biotech and diagnostics startups for no fees and no equity. Each gBETA program is capped at five companies to ensure meaningful engagement with program partners and other resources. Participants receive intensive, individualized coaching and access to gener8tor’s national network of mentors, customers, corporate partners and investors. The program is designed to help startups gain early customer traction on their product or idea, and establish metrics that can make them competitive applicants for full-time, equity-based accelerators or seed investment.
gBETA Medtech is a program of UEL and gener8tor. Boston Scientific is the founding partner of the gBETA
Medtech. The cohort receives mentorship support from Mayo Clinic, Medical Alley Association and University of Minnesota. UEL and gener8tor also receive support through a cooperative agreement with the U.S. Department of Health and Human Services’ BARDA DRIVe.
“We’re so fortunate to have such a diverse set of founders with expertise across the healthcare continuum,” said KC Caine, gBETA Director for the Medtech program. “Our founders are bringing high-impact innovations to the sector, and we’re excited to see how their companies grow.” After the 7-week program, the Showcase Day virtual event will provide an opportunity for the public to listen and learn more about the startups and network with the founders and other community members. Stay tuned for more information.
Startups interested in applying for future cohorts should contact gBETA Director KC Caine at kc@gener8tor.com.
About the Companies
Mother of Fact‘s on-demand HIPAA secure mobile app supports any mom as they navigate all baby feeding needs, serving the fragmented $14 billion market for pregnancy and baby care. This evidenced-based platform provides access to nutrition tracking, preventative monitoring, and daily coaching from licensed dietitians.
OmniVis developed a detection device to support international aid organizations and practicing physicians in diagnosing infectious diseases. OmniVis’ ultrasensitive handheld device provides a low cost solution to labor intensive lab testing, bringing accurate results directly to the point of care in under 30 minutes.
Q-rounds™ provides an in-hospital digital health solution that sends real-time updates for patients, their families, and the careteam on when to expect their doctor to arrive for inpatient rounds. In addition to empowering patients and hospital systems with time-transparency, Q-rounds offers one-click telehealth for those who can’t be at the bedside to seamlessly join rounds remotely right on cue. Q-rounds saves hospitals money by increasing hospital throughput, improving patient satisfaction, and decreasing medical
errors through bringing the entire team together for the most important moment of the hospital day – bedside rounds.
SingleTimeMicroneedles created a painless, removable, transdermal microneedle patch that can deliver vaccines in the comfort of a person’s home. STM’s vaccine delivery technology is the only platform engineered to deliver single or multiple dose vaccines in one application without needles or other equipment. By eliminating pain, refrigerated supply chains, and the need for clinic visits, STM’s patch reduces needle avoidance and improves overall vaccine efficacy and deployment efforts.
Tiumed’s high-performance, easy to adopt surgical platform targets benign prostatic hyperplasia (BPH) surgery, an enlarged prostate treatment 1 in 4 men will require in their lifetime. Tiumed’s patented design doubles the tissue removal rate and increases surgeon control, improving procedure times, procedure completeness and number of procedures performed.
About gener8tor:
gener8tor’s turnkey platform for the creative economy connects startup founders, investors, corporations,
universities, job seekers, musicians and artists. The gener8tor platform includes accelerators, skilling,
corporate programming and conferences with content on community growth, impact investing, diversity,
equity and inclusion, and innovation across education, agriculture, insurance, healthcare, and more.
Recently, gener8tor was named one of Fast Company’s Best Workplaces for Innovators. For more information, visit gener8tor.com.
About gBETA:
gBETA accelerates the growth of early-stage companies through its network-driven program. gBETA supports five teams per cohort and requires no fees and no equity. Since launching in 2015, gBETA
program alumni have raised $385M+ in capital and created 2,900+ jobs across the U.S. and Canada.
For more information, visit gener8tor.com/gbeta